TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets criteria for All-cause Dementia according to NIA-AA guidelines~2. Meets clinical criteria for one of the following disorders: Dementia associated with Parkinson's disease, Dementia with Lewy bodies, Possible or probable Alzheimer's disease, Frontotemporal degeneration spectrum disorders, Vascular dementia~3. Has an MMSE score ≥6 and ≤24~4. Has had psychotic symptoms for at least 2 months~5. Must be on a stable does of cholinesterase inhibitor or memantine, if applicable~6. If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential or must agree to use a clinically acceptable method of contraception for the duration of the study~Exclusion Criteria:~1. Has psychotic symptoms that are primarily attributable to a condition other than dementia~2. Has had a recent major depressive episode~3. Has experienced suicidal ideation or behavior within 3 months prior to study enrollment~4. Has evidence of a non-neurologic medical comorbidity or medication use that could substantially impair cognition~5. Has a history of ischemic stroke within the last 12 months or any evidence of hemorrhagic stroke~6. Has a known history of cerebral amyloid angiopathy (CAA), epilepsy, CNS neoplasm, or unexplained syncope~7. Has any of the following: greater than New York Heart Association (NYHA) Class 2 congestive heart failure, Grade 2 or greater angina pectoris, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, syncope due to an arrhythmia, an implantable cardiac defibrillator~8. Had a myocardial infarction within the last 6 months~9. Has a known personal or family history or symptoms of long QT syndrome~10. Has a significant unstable medical condition that could interfere with subject's ability to complete the study or comply with study procedures~11. Requires treatment with a medication or other substance that is prohibited by the protocol~Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Drug - Pimavanserin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of CD20 positive chronic lymphocytic leukemia (CLL)~* Either previously untreated or relapsed~* Measurable disease (at least one lesion \> 1.5 cm for NHL, or ALC \> 5,000 for CLL) see full protocol for additional criteria~Exclusion Criteria:~* Previously untreated NHL patients with Stage I and II disease (Ann Arbor classification)~* Previously untreated CLL patients with Stage 0-2 disease (Rai classification) unless specific treatment indications by NCCN guidelines exist (symptomatic, recurrent infections, end-organ function, cytopenias and steady disease progression).~see full protocol for additional criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- veltuzumab (Type: EXPERIMENTAL): veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis~* Early lower respiratory tract infection with P. aeruginosa,~Exclusion Criteria:~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.~* Administration of loop diuretics within 7 days prior to study drug administration.~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- TOBI (tobramycin inhaled solution)/Placebo (Type: EXPERIMENTAL): Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
- Placebo/TOBI (Type: PLACEBO_COMPARATOR): Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Live Attenuated Influenza H5N2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Age 18-49 years old~* Having Thai ID card or equivalent~* Are seronegative to the specific H5 influenza virus determined by antibody titer less than 1:40 by HAI test to the corresponding antigen.~* Anti HIV - Negative~* All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not more than 1.5 times of normal value)~* Able to read and write and sign written informed consent.~Exclusion Criteria:~* Known history of egg allergy~* Having had recently influenza infection confirmed as H5~* History of bronchial asthma~* History of chronic lung diseases~* History of chronic rhinitis~* History of immunodeficiency state~* History of immunosuppression~* History of heavy smoking (more than 5 rolls per day)~* History of alcoholic (pure drink 200 ml per day)~* Acute infectious and noninfectious diseases (within 2 weeks)~* Exacerbation of chronic diseases or cancer or HIV positives~* Anamnestic leukocytosis, hepatitis B and C positives~* The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment~* Participation in other research study or stop participant less than 1 month~* Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding~* Any concomitant medication with Aspirin~* Poultry workers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- A/17/turkey/Turkey/05/133 (H5N2) (Type: EXPERIMENTAL): 100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
- Placebo (Type: PLACEBO_COMPARATOR): 50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) Class I and II patients~* ≥18 years of age~* undergoing elective surgical procedures in the Saskatoon acute care hospitals of the Saskatoon Health Region~* requiring endotracheal intubation as a component of the anesthetic plan.~Exclusion Criteria:~* those who are physiologically unstable~* when there is urgency to proceed with surgery~* patients requiring rapid sequence induction~* those with respiratory distress~* those for whom the attending anaesthesiologist feels it would compromise safety for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard care (Type: SHAM_COMPARATOR): Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
- cuff palpation (Type: ACTIVE_COMPARATOR): Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WelChol® and Insulin in Treating Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 - 75 years, inclusive~* Diagnosed with type 2 diabetes~* Stable insulin therapy for 6 weeks~* Stable dose of any other antidiabetic medications for 90 days~* Hemoglobin A1c value between 7.5% to 9.5%~* C peptide greater than 0.5 ng/mL~* Prescribed ADA diet~Exclusion Criteria:~* History of type 1 diabetes or ketoacidosis~* History of pancreatitis~* Uncontrolled hypertension~* Allergy or toxic response to colesevelam or any of its components~* Serum LDL-C less than 60 mg/dL~* Serum TG greater than 500 mg/dL~* Body mass index (BMI) greater than 45 kg/m2-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Corticoids For Empyema And Pleural Effusion In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 1 and 14 year old.~* Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and radiological consolidation.~* Evidence of pleural effusion.~Exclusion Criteria:~* Allergy to any of the drugs included in the study.~* Immunodeficiency.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): * Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-45 years~* Primipara or multipara~* Singleton pregnancy ≥32 weeks~* American Society of Anesthesiologists physical status classification II to III~* Scheduled for cesarean section under spinal anesthesia~Exclusion Criteria:~* Baseline blood pressure ≥180 mmHg~* Body height \< 150 cm~* Body weight \> 100 kg or body mass index (BMI) ≥ 40 kg/m2~* Eclampsia or chronic hypertension~* Hemoglobin \< 7g/dl~* Fetal distress, or known fetal developmental anomaly

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Normal saline infusion simultaneous with subarachnoid block
- 0.025 μg/kg/min group (Type: EXPERIMENTAL): A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
- 0.050 μg/kg/min group (Type: EXPERIMENTAL): A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
- 0.075 μg/kg/min group (Type: EXPERIMENTAL): A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Saline Hypertonic in Preschoolers + CT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of CF as evidenced by one or more clinical features consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:~   1. A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT)~  2. A documented genotype with two disease-causing mutations in the CFTR gene~2. Informed consent by parent or legal guardian~3. Age ≥ 36 months and ≤72 months at screening visit~4. Ability to comply with medication use, study visits and study procedures as judged by the site investigator~5. Ability to cooperate with chest CT at the enrollment visit as determined by the lung function technician~Exclusion Criteria:~1. Chest CT within 8 months prior to the Screening visit~2. Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding screening or enrollment visit~3. Acute wheezing at screening or enrollment visit~4. Oxygen saturation \< 95% (\<90% in centers located above 4000 feet elevation) at screening or enrollment visit~5. Other major organ dysfunction, excluding pancreatic dysfunction~6. Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator~7. Investigational drug use within 30 days prior to screening or enrollment visit~8. Treatment with inhaled HS at any concentration within 30 days prior to screening or enrollment visit~9. Initiation (i.e. new prescription) of any inhaled hydrating agent such as mannitol or mucolytic agents such as dornase alpha within 30 days prior to the screening or enrollment visit~10. Chronic lung disease not related to CF~11. Inability to tolerate first dose of study treatment at the enrollment visit

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment Group (Type: EXPERIMENTAL): 7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
- Control Group (Type: ACTIVE_COMPARATOR): 0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is diagnosed with bipolar I disorder, most resent episode depressed~* Subject must have a lifetime history of at least one bipolar manic or mixed episode~* Subject must be taking lithium or divalproex at least 28 days prior to screening~Exclusion Criteria:~* History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode~* Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization~* Imminent risk of suicide or injury to self, others, or property

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study-specific procedures.~* Men and women who are between the ages of ≥18 and \<85 years.~* Self-reported active symptoms of OIC at screening (\<3 SBMs/week and experiencing ≥1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks); and Documented confirmed OIC (\<3 SBMs/week on average over the 2-week OIC confirmation period.~* Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression.~* Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 2-week OIC confirmation period and the 12-week treatment period, and to use only bisacodyl as rescue medication if a BM has not occurred within at least 72 hours of the last recorded BM.~Exclusion Criteria:~* Patients receiving Opioid regimen for treatment of pain related to cancer.~* History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.~* Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.~* Other issues to the gastrointestinal tract that could impose a risk to the patient.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral treatment
- 2 (Type: EXPERIMENTAL): Oral treatment
- 3 (Type: PLACEBO_COMPARATOR): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic pain~* Numeric Pain Rating Scale (NPRS) \>5 /10~* Age between 18 and 75 years old~Exclusion Criteria:~* Medical pain (headache, chest pain,...)~* Respiratory, renal or hepatic insufficiency~* Drug addiction~* Medical or Chirurgical sinus history~* Oxygene saturation \< 90%~* Systolic blood pressure \< 90mmHg~* Head injury with a neurological Glasgow Coma Scale (GCS) \< 14~* Opioid allergy~* Facial traumatism~* Patient unable do understand or assessing NPRS~* Opiates administration within 6 hours before admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IN Sufentanil AND IV Placebo (Type: EXPERIMENTAL): Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
- IV Morphine AND IN Placebo (Type: ACTIVE_COMPARATOR): Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hostile Bias Modification Training Online Study II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult aged 18 and older~2. Located in the United States or other primarily English speaking country.~3. Active Amazon Account.~Exclusion Criteria:~* Less than 18 years old.~* Not located in the United States or other primarily English speaking country.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HBMT (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete